I think it's because of the transverse myelitis scare during AZ's Phase 3 tests, combined with AZ's dosage quality control issues making it really hard to inter

I think it's because of the transverse myelitis scare during AZ's Phase 3 tests, combined with AZ's dosage quality control issues making it really hard to interpret efficacy data.